Andrew W Bollen
Overview
Explore the profile of Andrew W Bollen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3751
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez Almaraz E, Guerra G, Al-Adli N, Young J, Dada A, Quintana D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf024.
PMID: 40051658
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade...
2.
Lucas C, Al-Adli N, Young J, Gupta R, Morshed R, Wu J, et al.
Neuro Oncol
. 2024 Nov;
27(1):89-105.
PMID: 39560080
Background: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous...
3.
Terry M, Nguyen M, Tang V, Guney E, Bharani K, Dahiya S, et al.
Endocr Pathol
. 2024 Oct;
35(4):338-348.
PMID: 39388031
Pituitary neuroendocrine tumors (PitNET) that metastasize comprise ~ 0.2% of adenohypophyseal tumors are aggressive and are challenging to treat. However, many non-metastatic tumors are also aggressive. Herein, we review 21...
4.
Hadad S, Gupta R, Oberheim Bush N, Taylor J, Villanueva-Meyer J, Young J, et al.
Acta Neuropathol
. 2023 Dec;
147(1):3.
PMID: 38079020
Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive biomarkers are needed to identify those patients most likely to respond to specific treatments. Through prospective genomic profiling of...
5.
Terry M, Gupta R, Ravindranathan A, Wu J, Chan E, Bollen A, et al.
Acta Neuropathol
. 2023 Oct;
146(6):857-860.
PMID: 37821623
No abstract available.
6.
Guney E, Lucas C, Singh K, Pekmezci M, Fernandez-Pol S, Mirchia K, et al.
Blood Adv
. 2023 Mar;
7(13):3307-3311.
PMID: 36897259
No abstract available.
7.
Nielsen C, Zhang X, Raygor K, Wang S, Bollen A, Wang R
J Exp Med
. 2022 Nov;
220(2).
PMID: 36441145
Upregulation of Notch signaling is associated with brain arteriovenous malformation (bAVM), a disease that lacks pharmacological treatments. Tetracycline (tet)-regulatable endothelial expression of constitutively active Notch4 (Notch4*tetEC) from birth induced bAVMs...
8.
Lucas C, Sloan E, Gupta R, Wu J, Pratt D, Vasudevan H, et al.
Acta Neuropathol
. 2022 Aug;
144(4):747-765.
PMID: 35945463
Gliomas arising in the setting of neurofibromatosis type 1 (NF1) are heterogeneous, occurring from childhood through adulthood, can be histologically low-grade or high-grade, and follow an indolent or aggressive clinical...
9.
Chen V, Bollen A, Marco-Salazar P, Higgins R, Siso S
Front Vet Sci
. 2022 Jul;
9:905302.
PMID: 35782550
An axillary mass was detected in a 6-year-old, neutered, male, domestic short-haired cat during a wellness exam. Gross examination following surgical removal revealed a discrete, deep subcutaneous, discoid mass that...
10.
Kumar A, Mohamed E, Tong S, Chen K, Mukherjee J, Lim Y, et al.
Clin Cancer Res
. 2022 May;
28(13):2898-2910.
PMID: 35511927
Purpose: The immunosuppressive tumor microenvironment present in the majority of diffuse glioma limits therapeutic response to immunotherapy. As the determinants of the glioma-associated immune response are relatively poorly understood, the...